The currently available vaccines against influenza are viral strain specific and, hence, their
efficacy is limited when the circulating strain is not the one included in them. We review …

Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing
Abs against a broad range of variant strains, is an important strategy for the development of …

Influenza viruses infect approximately 20% of the global population annually, resulting in
hundreds of thousands of deaths. While there are Food and Drug Administration (FDA) …

The challenges of effective vaccination against influenza are gaining more mainstream
attention, as recent influenza seasons have reported low efficacy in annual vaccination …

Influenza is a vaccine preventable disease and vaccination remains the most effective
method of controlling the morbidity and mortality of seasonal influenza, especially with …

Influenza viruses cause seasonal epidemics as well as pandemics and are a significant
concern for human health. Current influenza virus vaccines show efficacy when they are …

Currently, aluminum salts and MF59 are the only vaccine adjuvants approved for human
use. With the development of new-generation vaccines (including recombinant subunit and …

The severity of the 2017–18 influenza season, combined with the low efficacy for some
vaccine components, highlights the need to improve our current seasonal influenza vaccine …

Introduction: Annual vaccination is one of the most efficient and cost-effective strategies to
prevent and control influenza epidemics. Most of the currently available influenza vaccines …

Numerous modern technological and scientific advances have changed the vaccine
industry. However, nearly 70 years of influenza vaccine usage have passed without …